- Home
- SPCB vs IGC Comparison
SPCB vs IGC Comparison
Compare SPCB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCB
- IGC
- Stock Information
- Founded
- SPCB 1988
- IGC 2005
- Country
- SPCB Israel
- IGC United States
- Employees
- SPCB N/A
- IGC N/A
- Industry
- SPCB Semiconductors
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SPCB Technology
- IGC Health Care
- Exchange
- SPCB Nasdaq
- IGC Nasdaq
- Market Cap
- SPCB 53.3M
- IGC 20.2M
- IPO Year
- SPCB N/A
- IGC N/A
- Fundamental
- Price
- SPCB $10.70
- IGC $0.38
- Analyst Decision
- SPCB Strong Buy
- IGC Strong Buy
- Analyst Count
- SPCB 1
- IGC 2
- Target Price
- SPCB $18.00
- IGC $3.88
- AVG Volume (30 Days)
- SPCB 129.8K
- IGC 6.7M
- Earning Date
- SPCB 08-14-2025
- IGC 08-07-2025
- Dividend Yield
- SPCB N/A
- IGC N/A
- EPS Growth
- SPCB N/A
- IGC N/A
- EPS
- SPCB 1.89
- IGC N/A
- Revenue
- SPCB $27,831,000.00
- IGC $1,271,000.00
- Revenue This Year
- SPCB $2.73
- IGC $15.26
- Revenue Next Year
- SPCB $22.87
- IGC $3.41
- P/E Ratio
- SPCB $5.55
- IGC N/A
- Revenue Growth
- SPCB 2.90
- IGC N/A
- 52 Week Low
- SPCB $2.55
- IGC $0.25
- 52 Week High
- SPCB $18.95
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- SPCB 55.03
- IGC 65.10
- Support Level
- SPCB $9.23
- IGC $0.30
- Resistance Level
- SPCB $10.97
- IGC $0.46
- Average True Range (ATR)
- SPCB 0.61
- IGC 0.02
- MACD
- SPCB -0.11
- IGC 0.01
- Stochastic Oscillator
- SPCB 65.97
- IGC 48.81
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.